INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy – Introgen, RPR/INGN 201

Author：  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.17, Iss.3, 2003-01, pp. : 216-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Leukemic phase and CSF involvement of diffuse large B‐cell lymphoma with a complex karyotype including a TP53 deletion

By  

Clinical Case Reports, Vol. 6, Iss. 1, 2018-01 ,pp. : 235-237

John Wiley & Sons Inc

Access to resources Recommend Favorite

pHi: a review of the literature

By SUTCLIFFE N P   MOSTAFA S M  

Clinical Intensive Care, Vol. 7, Iss. 5, 1996-10 ,pp. : 258-258

Ashgate Publishing Ltd

Access to resources Recommend Favorite

DTaP 5 -IPV-Hib Vaccine (Pediacel®)†: Profile Report

By Frampton James E.  

BioDrugs, Vol. 26, Iss. 2, 2012-04 ,pp. : 121-123

Adis International

Access to resources Recommend Favorite

FGF-4 Gene Therapy GENERX - Collateral Therapeutics: Ad5FGF4, Fibroblast Growth Factor-4 Gene Therapy GENERX - Collateral Therapeutics, GENERX

By  

BioDrugs, Vol. 16, Iss. 1, 2002-01 ,pp. : 75-76

Adis International

Access to resources Recommend Favorite

Distance-based reputation metrics are practical in P2P environments

By Grishchenko Victor S.  

International Journal of Metadata, Semantics and Ontologies, Vol. 1, Iss. 2, 2006-10 ,pp. : 133-140

Inderscience Publishers

Access to resources Recommend Favorite